dacarbazine

Dacarbazine (DTIC-Dome) is an antineoplastic agent. It has significant activity against melanomas.

Dacarbazine ( imidazole carboxamide) is a chemotherapy drug used to treat melanoma and Hodgkin's lymphoma.

Dacarbazine citrate is an alkylating agent used to treat cancers of the lymphatic system and malignant melanoma (a type of skin cancer) in patients with certain conditions: islet cell carcinoma (part of the pancreas) Soft tissue sarcoma (cancer of muscles

Pancopride（LAS 30451） is a novel, orally available, long-acting, selective 5-HT3 receptor antagonist that blocks nitrogen mustard and dacarbazine-induced vomiting.

RRD-251 is an Rb-Raf-1 interaction inhibitor that induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine[1].

CB10-277 is a synthetic derivative of dimethylphenyl-triazene related to dacarbazine, with antineoplastic properties. Related to the agent dacarbazine, CB10-277 is converted in vivo to a monomethyl triazene form that alkylates DNA, resulting in inhibition of DNA replication and repair; in addition, this agent may act as a purine analogue, resulting in inhibition of DNA synthesis, and may interact with protein sulfhydryl groups.